Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Zameel Cader of the Nuffield Department of Clinical Neurosciences will use MRC Technology’s commercialization services to advance new treatments for migraine pain control.

MRC Technology, a technology transfer organisation, is collaborating with Dr Zameel Cader to screen selective and potent potassium channel activators to develop novel therapeutic interventions in migraine. Drawing on MRC Technology’s commercialisation expertise in drug discovery, the project focuses on bringing to clinic more effective pain treatments arising from the work of Dr Cader’s group in identifying KCNK18, the first gene underlying typical migraine.

KCNK18 encodes a tandem-pore background potassium channel, TRESK, which is linked to causing migraines and controls the sensitivity of pain nerves in the brain. If TRESK is faulty or inactive, the body’s threshold to pain can be significantly lowered. Migraine is the most common neurological disorder, with prevalence estimated at 18.2% in females and 6.5% in males, and is characterised by a severe, recurring headache, often accompanied by nausea, vomiting and increased sensitivity to light and sound.

Dr Justin Bryans at MRC Technology, said: 'We are delighted to be working with Dr Cader and his team who have made such a significant discovery in the underlying causes of migraine. We are hopeful that our collaboration will lead to treatments that could not only prevent migraines, but could potentially result in a more general pain therapy with even wider impact.'

'Migraine is a major cause of disability worldwide and it has been estimated to be the most costly neurological disorder in Europe', commented Dr Cader. 'We have made a major step forward in our understanding of why people suffer with migraine and with MRC Technology’s wealth of drug discovery experience, we look forward to working with them to bring novel treatments to market.'

Read more information from ScienceDirect

photo credit: tudedude via photopin cc

Similar stories

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.